Hemispherian AS
Latest round
- Series A
Last raised
- Nov 2022
Total raised
- $4.3M
Investors
- 2
About Hemispherian AS
Founded in 2015 and based in Oslo, Norway, Hemispherian AS operates as a biotechnology research firm that develops new cancer treatments. The company is developing small molecule drugs (GLIX) that target the TET2 enzyme and activate the DNA damage response, resulting in cancer cell death.
Who invested in Hemispherian AS
2 investors across 2 rounds
See all investors in Hemispherian AS
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Hemispherian AS
Who invested in Hemispherian AS?
Hemispherian AS has 2 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Hemispherian AS raised?
Hemispherian AS has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Hemispherian AS last raise money?
Hemispherian AS's most recent round on record is a Series A, in Nov 2022.
What does Hemispherian AS do?
Founded in 2015 and based in Oslo, Norway, Hemispherian AS operates as a biotechnology research firm that develops new cancer treatments.
Where is Hemispherian AS headquartered?
Hemispherian AS is headquartered in Oslo, Norway.
Which VCs invest in companies like Hemispherian AS?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Hemispherian AS's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Hemispherian AS? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.